Acute phase response and mineral status following low dose intravenous zoledronic acid in children

被引:70
作者
Munns, Craig F.
Rajab, Mansoor H.
Hong, Janet
Briody, Julie
Hoegler, Wolfgang
McQuade, Mary
Little, David G.
Cowell, Christopher T.
机构
[1] Childrens Hosp Westmead, Inst Endocrinol & Diabet, Westmead, NSW 2145, Australia
[2] Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia
[3] Childrens Hosp Westmead, Dept Nucl Med, Westmead, NSW, Australia
[4] Childrens Hosp Westmead, Dept Orthopaed Surg, Westmead, NSW, Australia
关键词
zoledronic acid; flu-like symptoms; hypocalcaemia; children;
D O I
10.1016/j.bone.2007.05.002
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Introduction: Previous reports have shown a high frequency of hypocalcaemia and flu-like symptoms following an initial first zoledronic acid dose of 0.02-0.025 mg/kg in children. Methods: We systematically evaluated the mineral status and symptomatology of 63 children with a variety of bone disorders treated with an initial zoledronic acid dose of 0.0125 mg/kg. The Mann-Whitney U test, chi-squared test and Fisher's exact test were used as appropriate. Results: 0.0125 mg/kg zoledronic acid reduced the incidence and intensity of hypocalcaemia but not the incidence of the flu-like symptoms compared to higher doses. Within the low dose cohort, flu-like symptoms were associated with an acute inflammatory response. Children who became hypocalcaemic received a higher dose in relation to their body mass index and body surface area. Conclusion: Reducing the initial zoledronic acid dose in children decreased the incidence of hypocalcaemia and thus improved safety. Dosing on the basis of body mass index or body surface area instead of body weight may further reduce the incidence of hypocalcaemia. (C) 2007 Elsevier Inc. All rights reserved.
引用
收藏
页码:366 / 370
页数:5
相关论文
共 16 条
[1]
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta [J].
Åström, E ;
Söderhäll, S .
ARCHIVES OF DISEASE IN CHILDHOOD, 2002, 86 (05) :356-364
[2]
Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO
[3]
2-0
[4]
Recommendations for zoledronic acid treatment of patients with bone metastases [J].
Berenson, JR .
ONCOLOGIST, 2005, 10 (01) :52-62
[5]
A dose-finding study of zoledronate in hypercalcemic cancer patients [J].
Body, JJ ;
Lortholary, A ;
Romieu, G ;
Vigneron, AM ;
Ford, J .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (09) :1557-1561
[6]
Prolonged hypocalcemia after treatment with zoledronic acid in a patient with prostate cancer and vitamin D deficiency [J].
Breen, TL ;
Shane, E .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (08) :1531-1532
[7]
Fever after zoledronic acid administration is due to increase in TNF-α and IL-6 [J].
Dicuonzo, G ;
Vincenzi, B ;
Santini, D ;
Avvisati, G ;
Rocci, L ;
Battistoni, F ;
Gavasci, M ;
Borzomati, D ;
Coppola, R ;
Tonini, G .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2003, 23 (11) :649-654
[8]
Fleisch H., 2000, Bisphosphonates in bone diseases: from the laboratory to the patient
[9]
Short-term safety assessment in the use of intravenous zoledronic acid in children [J].
Hogler, W ;
Yap, F ;
Little, D ;
Ambler, G ;
McQuade, M ;
Cowell, CT .
JOURNAL OF PEDIATRICS, 2004, 145 (05) :701-704
[10]
Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: Clinical and histomorphometric outcome [J].
Munns, CFJ ;
Rauch, F ;
Travers, R ;
Glorieux, FH .
JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (07) :1235-1243